표준 치료에 실패한 진행성 또는 전이성 암 환자를 대상으로 한 ITC-6146RO 연구
표준 치료에 실패한 진행성 또는 전이성 암 환자를 대상으로 ITC-6146RO의 안전성, 내약성, 약동학 및 예비 항종양 효능을 평가하기 위한 다중 코호트를 포함한 1a/b상, 개방형, 다기관, 최초 인체용, 용량 증량/확장 연구
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal biological dose (OBD).
In Phase 1b, the recommended phase 2 dose (RP2D) chosen from Phase 1a will be evaluated to further investigate safety, tolerability, pharmacokinetic (PK) and anti-tumor efficacy of ITC-6146RO.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Seoul
-
Seoul, Seoul, 대한민국, 05505
- Asan Medical Center
-
Seoul, Seoul, 대한민국, 06351
- Samsung Medical Center
-
Seoul, Seoul, 대한민국, 03722
- Severance Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adult males and females aged ≥ 19 years (Korea) or ≥ 18 years (United States)
- Patients must be individuals who have voluntarily agreed to participate in the study after receiving a detailed explanation and fully understanding the nature of the clinical trial, and who have provided written informed consent.
- Pathological confirmation of malignancy and evidence of metastatic or surgically unresectable disease
- Patients must have at least one evaluable or measurable lesion based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1). However, for patients with prostate cancer, eligibility will be determined based on Prostate Cancer Working Group 3 (PCWG3)
- Patients who have received standard therapies and have no remaining clinically available approved treatment options.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Estimated life expectancy of ≥ 3 months
Exclusion Criteria:
- Inability to comply with study and follow-up procedures
- Patients with a prior history of anticancer therapy before the first dose
- History of another active malignancy within the past 3 years
- Patients with central nervous system metastases, leptomeningeal disease, or spinal cord compression.
- Patients who are currently participating in a clinical trial or have participated in a clinical trial involving a medical device or investigational product within 28 days prior to the first administration of ITC-6146RO
- Has prior treatment with duocarmycin-containing agents
- Pregnancy, lactation, or breastfeeding
- Known Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV) infection with active disease exception of the following conditions.
- Tuberculosis with active disease
- Active infection necessitating systemic therapy
- Prior allogenic bone marrow transplantation or solid organ transplantation
- History of autoimmune disease, treatment with systemic immunosuppressive medications
- Patients with clinically significant pulmonary disease
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Phase 1a/b
The study consists of a Phase 1a dose-escalation part and a Phase 1b dose-expansion part. |
ITC-6146RO will be administered as an intravenous (IV) infusion at protocol-specified dose levels and schedules in Phase 1a (dose escalation) and Phase 1b (dose expansion). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1a (Dose Escalation) Incidence of Adverse Events (AEs)
기간: Through study completion (Up to 2 years)
|
Grade 3 and 4 AEs, Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Dose-limiting toxicities (DLTs) and AEs leading to discontinuation of study treatment, Evaluation of all-grade cardiac, renal, and pulmonary AEs , n, (%) |
Through study completion (Up to 2 years)
|
|
Phase 1b (Dose Expansion) Incidence of AEs
기간: Through study completion (Up to 2 years)
|
Grade 3 and 4 AEs, TEAEs, SAEs and AEs leading to discontinuation of study treatment, Evaluation of all-grade cardiac, renal, and pulmonary AEs, n, % |
Through study completion (Up to 2 years)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1a (Dose Escalation) Maximum Tolerated Dose (MTD) or Optimal Biological Dose (OBD) of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
MTD/OBD will be reported as the final selected dose level for further investigation from Phase 1a dose escalation. MTD is determined by DLTs observed during the prespecified DLT observation period, and OBD is determined by meeting prespecified biological activity criteria (as defined in the protocol). |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma AUClast following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma AUCinf following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Maximum Observed Plasma Concentration (Cmax) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma Cmax following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Terminal Elimination Half-life (t1/2) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma terminal elimination half-life (t1/2) following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Time to Maximum Observed Plasma Concentration (Tmax) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma Tmax following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Apparent Clearance (CL) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma apparent clearance (CL) following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Apparent Volume of Distribution (Vz) After Single-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma apparent volume of distribution (Vz) following a single dose of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma AUClast following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Maximum Observed Plasma Concentration at Steady State (Cmax,ss) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma Cmax,ss (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Trough Plasma Concentration at Steady State (Ctrough,ss) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma Ctrough,ss (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Average Plasma Concentration Over the Dosing Interval at Steady State (Cav,τ) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma Cav,τ (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Terminal Elimination Half-life at Steady State (t1/2,ss) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma terminal elimination half-life at steady state (t1/2,ss) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Time to Maximum Observed Plasma Concentration at Steady State (Tmax,ss) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma Tmax,ss (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Apparent Clearance at Steady State (CLss) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma apparent clearance at steady state (CLss) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Apparent Volume of Distribution at Steady State (Vss) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Plasma apparent volume of distribution at steady state (Vss) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Accumulation Ratio After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Accumulation ratio (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Peak-to-Trough Fluctuation (PTF) After Multiple-Dose Administration of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Peak-to-trough fluctuation (PTF) (as applicable) following multiple-dose administration of ITC-6146RO will be calculated from plasma concentration-time data and summarized descriptively. |
Through study completion (Up to 2 years)
|
|
Phase 1a (Dose Escalation) Incidence of Anti-Drug Antibodies (ADAs) to ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Percentage of participants with detectable ADAs to ITC-6146RO (ADA-positive) based on a validated immunoassay. |
Through study completion (Up to 2 years)
|
|
Phase 1b (Dose Expansion) Population Pharmacokinetic (PopPK) Parameters of ITC-6146RO
기간: Through study completion (Up to 2 years)
|
PopPK parameters (e.g.,clearance and volume of distribution) will be estimated using PopPK modeling based on measured ITC-6146RO concentrations. |
Through study completion (Up to 2 years)
|
|
Phase 1b (Dose Expansion) Incidence of Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) to ITC-6146RO
기간: Through study completion (Up to 2 years)
|
Percentage of participants with detectable ADAs, including NAbs, to ITC-6146RO, as determined by validated immunoassay and neutralization assays (as applicable). |
Through study completion (Up to 2 years)
|
|
Phase 1a/b (Dose Escalation, Dose Expansion) Objective Response Rate (ORR) by Investigator per RECIST v1.1
기간: Through study completion (Up to 2 years)
|
ORR will be assessed by the investigator per RECIST v1.1 |
Through study completion (Up to 2 years)
|
|
Phase 1a/b (Dose Escalation, Dose Expansion) Duration of Response (DoR) by Investigator per RECIST v1.1
기간: Through study completion (Up to 2 years)
|
DoR will be assessed by the investigator per RECIST v1.1 |
Through study completion (Up to 2 years)
|
|
Phase 1a/b (Dose Escalation, Dose Expansion) Time to Response (TTR) by Investigator per RECIST v1.1
기간: Through study completion (Up to 2 years)
|
TTR will be assessed by the investigator per RECIST v1.1 |
Through study completion (Up to 2 years)
|
|
Phase 1a/b (Dose Escalation, Dose Expansion) Progression-Free Survival (PFS) by Investigator per RECIST v1.1
기간: Through study completion (Up to 2 years)
|
PFS will be assessed by the investigator per RECIST v1.1 |
Through study completion (Up to 2 years)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Phase 1b (Dose Expansion) Association Between ITC-6146RO Pharmacokinetic Parameters and Efficacy and Safety Endpoints
기간: Through study completion (Up to 2 years)
|
Correlation between ITC-6146RO pharmacokinetic (PK) parameters and selected efficacy, safety, and exploratory endpoints. Efficacy endpoints may include objective response rate (ORR) and progression-free survival (PFS). Associations will be evaluated using appropriate exposure-response analyses. |
Through study completion (Up to 2 years)
|
|
Phase 1a/b (Dose Escalation, Dose Expansion) Overall Survival (OS)
기간: Through study completion (Up to 2 years)
|
OS is defined as the time from randomization until death from any cause. |
Through study completion (Up to 2 years)
|
|
Phase 1a/b (Dose Escalation, Dose Expansion) Association Between B7-H3 Expression in Tumor Tissue and Anti-Tumor Efficacy
기간: Through study completion (Up to 2 years)
|
Correlation between B7-H3 expression in tumor tissue assessed by immunohistochemistry (IHC) and anti-tumor efficacy endpoints, including objective response rate (ORR) and progression-free survival (PFS). ORR is defined as the proportion of participants with confirmed complete or partial response, and PFS as time to disease progression or death per protocol-defined criteria. Associations will be evaluated using appropriate statistical methods. In participants with metastatic castration-resistant prostate cancer (mCRPC), PSA response rate (≥50% decline from baseline) and time to PSA progression will also be assessed. |
Through study completion (Up to 2 years)
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .